Veradermics, Incorporated Common Stock (MANE)

Veradermics (NYSE:MANE) said results from the female arms of Study 207, a phase II open-label trial of VDPHL01 for mild to moderate pattern hair loss, showed what company executives described as a strong proof-of-concept signal for the oral treatment. Chief Executive Officer Dr. Reid Waldman said t

Veradermics develops novel dermatology treatments, targeting both adult and pediatric markets with a research-driven approach.